Back
to sessions
Sep 29
Scientific
MODERATOR(S)
Sean McBride, MD, MPH - Memorial Sloan Kettering Cancer Center
Shalini Moningi, MD - Cleveland Clinic Taussig Cancer Institute
Credits
| AMA PRA Category 1 Credits: | 1.25 |
Presentations
-
12:30pm - 12:40pm ET
A Randomized Phase II Study of Enhanced AR Blockade with Enzalutamide In High-Risk Patients with Biochemical Relapse Undergoing Salvage Radiation: Final Results from RTOG 3506 (STEEL)
Speaker: Edwin Posadas, MD - Cedars-Sinai Medical Center, Los Angeles -
12:40pm - 12:50pm ET
The Role of Docetaxel In Addition to Salvage Radiation and Androgen Deprivation In Men with High Risk Prostate Cancer Post-Prostatectomy: Results of NRG GU002
Speaker: Mark Hurwitz, MD, FASTRO - New York Medical College/Westchester Medical Center Health, Valhalla -
12:50pm - 01:00pm ET
PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT) : Five-Year Primary Endpoint of a Phase 2 Randomized Controlled Trial
Speaker: Colin Belliveau, MD - Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal -
01:00pm - 01:10pm ET
Postoperative Stereotactic Body Radiotherapy (SBRT) to the Prostate Bed for Biochemical Recurrence: Results from the Prospective Multicenter POPART Trial
Speaker: Stefano Arcangeli, MD - University of Milan Bicocca, Monza -
01:10pm - 01:20pm ET
Phase II Results of the Randomized StereoBed Trial: Salvage Stereotactic Body Radiotherapy to the Prostate Bed for Biochemical Recurrence after Radical Prostatectomy
Speaker: Pauline De Bruyn, - Department of Radiation Oncology, Institut Jules Bordet, Brussels, Belgium, Belgium -
01:20pm - 01:30pm ET
Early Salvage Stereotactic Radiotherapy (esSBRT) for Biochemical Failure after Radical Prostatectomy: Preliminary Results
Speaker: Marta Bottero, MD, PhD - Regina Elena National Cancer Institute, Rome -
01:30pm - 01:40pm ETSpeaker: Daniel Krauss, MD, FASTRO - Beaumont Health, Royal Oak